Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28960351 | 0.92 | PTGS1 (0.37) | PTGS1AHRNQO2NFE2L2HDAC1 | |
| SCHEMBL26426000 | 0.92 | PTGS1 (0.37) | PTGS1AHRNQO2NFE2L2HDAC1 | |
| SCHEMBL26425423 | 0.89 | CYP1A1 (0.42) | NFE2L2CYP1A2 | |
| SCHEMBL26425426 | 0.89 | NFE2L2 (0.47) | NFE2L2FBP1CA1CA2CA9 | |
| SCHEMBL26425434 | 0.87 | NFE2L2 (0.40) | PTGS1NFE2L2CYP1A2 | |
| SCHEMBL26425430 | 0.87 | NFE2L2 (0.39) | PTGS1AHRNFE2L2 | |
| SCHEMBL26425412 | 0.84 | AHR (0.43) | AHRNFE2L2 | |
| SCHEMBL24254424 | 0.84 | MAPT (0.39) | — | |
| SCHEMBL26425427 | 0.83 | ALDH1A1 (0.41) | — | |
| SCHEMBL26425416 | 0.82 | NFE2L2 (0.47) | PTGS1NQO2NFE2L2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| CN-111333672-A | Sterol regulatory element binding protein and acidic nucleoplasm DNA binding protein-1 inhibitor, and preparation method and application thereof | 中国医学科学院放射医学研究所 | 2020-06-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | TP53, ANXA5, MCL1 | PTGS1 2360/4885AHR 3843/4885NQO2 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.